The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? (Q37945533)

25 August 2017

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? (English)

1 reference

25 August 2017

Moriah H Nissan

1

1 reference

PubMed ID

21997758

25 August 2017

David B Solit

series ordinal

2

1 reference

PubMed ID

21997758

25 August 2017

language of work or name

1 reference

1 December 2011

1 reference

25 August 2017

Current Oncology Reports

1 reference

25 August 2017

13

1 reference

25 August 2017

479-487

1 reference

25 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-011-0198-4

25 August 2017

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Transcriptional regulation by MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Modulation of signalling by Sprouty: a developing story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Pathologic features and biologic importance of colorectal serrated polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

How melanomas bypass new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0198-4

Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669

21 January 2018

1 reference

12 December 2020

Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

1 reference

12 December 2020

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

1 reference

12 December 2020

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

Active Ras induces heterodimerization of cRaf and BRaf

1 reference

12 December 2020

10.1007/S11912-011-0198-4

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21997758